Question Bank › Deprived of a working part of itself

Deprived of a working part of itself

Deprived of a working part of itself: management describes an already-proven piece of the business it is currently unabl

Calls Tested

333

Answered YES

Hit Rate

rare by design

Agios Pharmaceuticals, Inc. (AGIO) — this company's answers

NO on the Q3 2018 call 2018-11-01 C

The model's full reasoning — Q3 2018 call → NOWe need to determine if the transcript describes a situation where a proven part of the business is being held back by the company itself, and management is actively working to feed it, with the numbers not yet showing its full potential. Let's analyze the transcript. The company is Agios Pharmaceuticals. They have products: TIBSOVO (ivosidenib) for IDH1 mutant AML, and IDHIFA (enasidenib) for IDH2 mutant AML. They also have other pipeline drugs. The question asks: "On this call, does management describe that ONE IDENTIFIABLE PART OF THE COMPANY'S BUSINESS HAS ALREADY PROVEN ITSELF IN REAL USE, and that the company is CURRENTLY UNABLE TO GIVE IT WHAT IT NEEDS — so that management's own account of the period is about a working thing being held back by something inside the company, together with the concrete steps now being taken to release it?" We need to find if there is a specific part of the business that is proven, but the company is holding it back due to internal constraints, and they are actively working to fix that. Look at the launch of TIBSOVO. They report net sales of $4.5 million for the first partial quarter. They talk about increasing testing rates, physician awareness, etc. But is there any mention of the company being unable to supply something? For example, manufacturing capacity, sales force, etc.? Steve Hoerter says: "Since our launch in July, our team of senior hematology sales consultants has had approximately 2,000 customer interactions... Increasing testing rates of the IDH mutation is a key strategic imperative... we're encouraged with the steady growth... we're pleased with the uptake we are seeing." He also says: "we are not aware of any payer-related coverage issues." So no mention of supply constraints. Andrew Hirsch talks about cost of sales and inventory. He says: "We ended the third quarter with what we believe is a reasonable level of TIBSOVO inventory to expect going forward." So inventory is fine. There is no mention of the company being unable to give TIBSOVO what it needs. The launch seems to be going well, and they are not describing any internal shortfall. What about other parts? For example, the mitapivat program in PK deficiency. They say: "we continue to make progress in our pivotal program for Mitapivat in pyruvate kinase deficiency...

← Back to the full AGIO analysis

Show the exact prompt the model was given

Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that ONE IDENTIFIABLE PART OF THE COMPANY'S BUSINESS HAS ALREADY PROVEN ITSELF IN REAL USE, and that the company is CURRENTLY UNABLE TO GIVE IT WHAT IT NEEDS — so that management's own account of the period is about a working thing being held back by something inside the company, together with the concrete steps now being taken to release it?

Answer YES when management's own words convey, in whatever form fits the business, ONE coherent situation in which all three of the following come through as a present-tense reality:

(1) A PROVEN PIECE, ALREADY WORKING. Management points to a specific, identifiable part of the company — a product, service, offering, site, format, program, market, customer set, capability, or line of business — that is already producing real results in actual use: real customers, orders, volumes, utilization, output, repeat business, or performance in the recent period that management can describe concretely. Management treats the question of whether this thing works as settled: it has been demonstrated, not projected. It need not be large; it may be a small part of the company today.

(2) THE COMPANY ITSELF IS WHAT IS HOLDING IT BACK. Management conveys, directly or plainly in substance, that this proven piece is currently getting LESS THAN IT COULD USE from the company — because the company cannot presently supply enough of something it must provide. The starved input may take whatever form fits the business and any genuine version counts: production or service capacity; inventory, units, or material; qualified people, crews, clinicians, or installers; facilities, sites, space, or equipment; sales, field, or support coverage; management attention or engineering bandwidth; capital or working capital the company must ration across competing uses; systems or infrastructure the offering runs on. What matters is that the shortfall is INTERNAL AND ATTACHED TO THIS SPECIFIC PROVEN PIECE — management is describing something that works and that it cannot yet feed properly — rather than a general claim of being busy, a shortage of purchased inputs alone, or weak demand.

(3) MANAGEMENT IS ACTIVELY WORKING TO FEED IT, AND SAYS THE NUMBERS DO NOT YET SHOW WHAT IT CAN DO. Management describes real, already-underway steps to close that specific shortfall — adding the capacity, hiring the people, building or opening the facilities, funding it, reallocating resources toward it from elsewhere in the company, securing the supply, or standing up the systems — presented as in motion or committed rather than contemplated. And management conveys, directly or plainly in substance, that the results just reported reflect this piece operating in its constrained state, so what it has contributed so far understates what it is expected to contribute once properly supplied. Candor about how long the fix takes, what it costs, or how much business is being left on the table strengthens rather than weakens a YES.

The essence is ONE phenomenon: inside the company there is something that demonstrably works, the company is presently the reason it is not bigger, and management is spending money and effort to remove itself as the obstacle. The industry, the nature of the proven piece, and the form of the starved input may vary widely.

Answer NO if the part of the business being discussed is unproven — a plan, a pilot without results, a launch with nothing sold, an opportunity, or a market the company has not yet entered. NO if the company is comfortably supplying everything that part of the business needs, however strong the results. NO if the limiting factor described is external and general — weak demand, competition, pricing, macro conditions, or an industry-wide shortage of purchased inputs — with no internal shortfall attached to a specific working piece of the company. NO if the constraint is described as trivial, transitory, already resolved, or a normal seasonal squeeze. NO if management describes the shortfall but no concrete action already underway to close it, or the response is only planned, budgeted for later, or contingent on financing or approvals not yet obtained. NO if the additions being made are the company's ordinary annual expansion or maintenance, with no sense that a specific proven piece has been going underfed. NO if the proven piece is already being supplied to its full potential and its contribution is fully reflected in the reported results. NO if management is chiefly cutting back, deprioritizing, or exiting the piece in question, or is explaining away its underperformance. NO if the situation appears only in an analyst's question or characterization that management does not itself affirm.

Use only the supplied transcript. Answer only YES or NO.

No call in the tested sample answered YES — this hypothesis came up empty, which is itself a result.

How the model reasoned

SCPH · Q3 2023 → NO我们根据提供的财报电话会议记录，判断是否符合问题描述的情况。问题核心是：管理层是否描述了一个已经证明有效的业务部分，但公司目前无法充分支持它，导致其表现受限，并且正在采取措施解决。在电话会议中，管理层讨论了FUROSCIX的商业化进展。他们提到第三季度净收入380万美元，环比增长138%，处方量、处方医生数量和每张处方的剂量都在增加。他们提到增加了12个销售区域，使销售团队达到66个区域，并预计这些新增将在第四季度产生积极影响。他们还提到与支付方的谈判，包括与大型综合医疗网络的协议，以及政府退休人员处方集的覆盖。关键点：管理层是否说这个产品已经证明有效，但公司内部资源不足？他们提到增加了销售代表，但这是否意味着之前销售代表不足？他们提到“我们增加了12个销售区域”，但这是否是常规扩张？他们还说“我们计划达到约110个销售代表”，但尚未明确何时增加。他们提到“我们正在积极与支付方谈判”，但这是否是内部限制？问题要求：一个可识别的业务部分已经证明有效，但公司目前无法给它所需的东西，导致其表现受限，并且正在采取措施解决。管理层是否明确说这个产品被内部因素阻碍？他们提到“我们增加了12个销售区域，但它们在第三季度末才加入，因此没有对第三季度结果产生重大贡献”，这暗示销售代表不足是限制因素。但他们是否说公司无法提供足够的销售代表？他们计划增加更多，但这是否是“正在采取行动”？他们提到“我们计划在明年上半年增加更多”，但这是否是“正在”？另外，他们提到支付方覆盖是限制因素，但那是外部因素。他们提到“我们正在与支付方谈判”，但那是外部。关键：管理层是否说这个产品已经证明有效，但公司内部资源不足？他们提到销售代表增加，但那是常规扩张还是因为产品被证明有效而需要更多？他们提到“我们增加了12个销售区域，以应对需求”，这暗示需求强劲，但公司需要更多销售代表来支持。但这是否是“公司本身在阻碍”？他们是否说“我们无法提供足够的销售代表”？他们提到“我们计划达到110个”，但尚未达到。另外，他们提到“我们正在积极与支付方谈判”，但那是外部。我认为，管理层没有明确说“公司内部资源不足”导致产品受限。他们提到增加销售代表，但那是为了应对需求，而不是说之前不足。他们也没有说“结果没有反映潜力”，而是说新增销售代表将在第四季度产生积极影响，这暗示当前结果可能没有完全反映潜力，但那是由于时间，而不是内部短缺。问题要求“公司本身是阻碍”，但这里似乎没有明确说。他们提到“我们增加了12个销售区域”，但那是为了扩大覆盖，而不是因为之前不足。他们也没有说“我们无法提供足够的销售代表”。因此，我认为答案是否定的。管理层没有描述一个被内部资源限制的已证明部分。他们描述的是增长和扩张，但那是正常的业务发展。所以，答案应为NO。

UFI · Q4 2021 → NOWe need to determine if the transcript describes a situation where a proven part of the business is being held back by the company itself, and management is actively working to feed it, with numbers not yet reflecting its potential. Let's analyze the transcript. Key points: - Management discusses strong Q4 results, with revenue growth, EBITDA, etc. - They mention REPREVE sales up 30% for the quarter, up 16% vs 2019, hang tags up 60%. They see sustainability as a driving force. - They mention regional businesses: North America, Asia, Brazil. Asia had record revenue, Brazil overdelivered, started selling REPREVE. - They mention increasing capital investment over next 3 years for new yarn texturing innovation called EvoCooler, from Oerlikon. This equipment will give significant efficiencies in productivity, energy consumption, operator safety. It will make them more profitable, give more plant capacity, and allow them to be more competitive against imports. - Eddie Ingle: "we are planning to continue these investments during fiscal year 2022, resulting in an elevated level of capital spending. These investments are necessary to meet what we expect will be a continued demand for our virgin and recycled products in future periods." - They discuss inflationary pressures, raw material costs, especially recycled plastic bottle flake costs increased significantly. They are taking pricing actions. - They mention trade petitions against countries, expected to provide benefits to sales volumes and cost absorption. - They discuss REPREVE growth, brand placements, etc. - They give guidance for fiscal 2022: net sales increase of 10% or more, operating income and adjusted EBITDA broadly consistent with fiscal 2021, effective tax rate 35-40%, capital expenditures $40-45 million primarily for new yarn texture machinery. Now, the question: Does management describe that ONE IDENTIFIABLE PART OF THE COMPANY'S BUSINESS HAS ALREADY PROVEN ITSELF IN REAL USE, and that the company is CURRENTLY UNABLE TO GIVE IT WHAT IT NEEDS — so that management's own account of the period is about a working thing being held back by something inside the company, together with the concrete steps now being taken to release it? We need to identify a specific part of the business that is proven and working, but is being held back by an internal constraint, and management is actively working to feed it.

ES · Q1 2024 → NOWe need to determine if the transcript describes a situation where a proven part of the business is being held back by the company itself, and management is actively working to feed it, with numbers not yet showing its potential. Key elements: (1) proven piece already working, (2) company itself is holding it back (internal shortfall), (3) management actively working to close the shortfall and says results understate potential. Look for such a narrative in the transcript. The transcript discusses offshore wind sale, Connecticut regulatory issues, capital cuts, etc. There is mention of Connecticut regulatory environment discouraging investment, and they are cutting capital there. That is more about cutting back, not feeding a proven piece. What about the New Hampshire solar? They are evaluating, not yet proven. What about the ESMP in Massachusetts? That's a plan, not yet proven. What about the water business? They are reviewing for sale, not feeding. What about the offshore wind? They are selling it, not feeding. What about the core utility business? They are investing, but is there a specific proven piece being held back? Possibly the resiliency program in Connecticut? They have a $300 million program that has been effective, but they are cutting back due to regulatory issues. That is the opposite. The question asks: "does management describe that ONE IDENTIFIABLE PART OF THE COMPANY'S BUSINESS HAS ALREADY PROVEN ITSELF IN REAL USE, and that the company is CURRENTLY UNABLE TO GIVE IT WHAT IT NEEDS — so that management's own account of the period is about a working thing being held back by something inside the company, together with the concrete steps now being taken to release it?" Look for a part that is working well but is underfunded or under-resourced due to internal decisions, and management is taking steps to fix that. In the transcript, there is discussion about Connecticut regulatory environment discouraging investment. They are cutting capital there. That is not feeding a proven piece; it's cutting. What about the natural gas distribution? They had higher earnings. No mention of being held back. What about the electric transmission? They are investing, but no mention of being held back. What about the storm response? They restored customers quickly, but that's not a business piece. What about the offshore wind? They are selling it, so not feeding.

Deprived of a working part of itself

Agios Pharmaceuticals, Inc. (AGIO) — this company's answers

How the model reasoned

More from the question bank